GLP-1 medications are not exclusively for people with diabetes. The FDA has approved semaglutide (Wegovy) and tirzepatide (Zepbound) for chronic weight management in non-diabetic adults who have obesity, or who are overweight with at least one weight-related health condition. If you do not have diabetes but have struggled to lose weight through diet and exercise alone, you may qualify for a GLP-1 prescription.
More than 70 percent of American adults are classified as overweight or obese, and the vast majority of them do not have diabetes. For years, these patients had limited medical options: surgery, or whatever the current diet trend promised. GLP-1 medications have changed that. Clinical trials in non-diabetic populations show weight loss outcomes that significantly outperform anything previously available without surgery. This article covers how these medications work outside a diabetic context, who qualifies, what the research shows, and what a complete program looks like beyond a prescription.
1. What GLP-1 Is and How It Causes Weight Loss
GLP-1 stands for glucagon-like peptide-1, a hormone produced naturally in your gut after you eat. Its role is to signal your brain that you are full, slow the rate at which food leaves your stomach, and support the regulation of insulin. In healthy individuals, this hormone is part of the natural satiety response after a meal. The problem is that a natural GLP-1 signal lasts only a few minutes.
GLP-1 receptor agonist medications mimic this hormone but with a far longer duration of action. A once-weekly injectable GLP-1 medication keeps those satiety signals continuously active, reducing hunger between meals and lowering the neurological reward response to food. Appetite drops. Cravings decrease. Eating past the point of fullness — something many people do habitually rather than out of genuine hunger — stops feeling automatic.
In people with type 2 diabetes, GLP-1 medications also help lower blood sugar by stimulating insulin release in a glucose-dependent way. In non-diabetic patients, blood sugar regulation is a secondary effect. The primary driver of weight loss is appetite suppression and satiety enhancement, both of which are effective regardless of blood sugar status.
2. Who Qualifies for GLP-1 Without Diabetes
The FDA eligibility criteria for GLP-1 weight loss therapy are specific. A non-diabetic adult may qualify if they meet one of the following thresholds:
| BMI | Additional Requirement |
|---|---|
| 30 or higher (obesity) | None required |
| 27 or higher (overweight) | At least one weight-related health condition |
Weight-related health conditions that may qualify a patient alongside a BMI of 27 or above include high blood pressure, high cholesterol (dyslipidemia), insulin resistance or prediabetes, polycystic ovary syndrome (PCOS), obstructive sleep apnea, and elevated cardiovascular risk. These criteria apply independently of diabetes status.
Final eligibility is always determined by a licensed medical provider after a full review of your health history. A BMI that meets the threshold does not guarantee a prescription. Known contraindications include a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a history of pancreatitis.
3. FDA-Approved GLP-1 Medications for Non-Diabetic Weight Loss
Two GLP-1 medications currently hold FDA approval for chronic weight management in non-diabetic adults:
Semaglutide (Wegovy)
A GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. The FDA approved Wegovy for chronic weight management in June 2021, specifically for adults without diabetes meeting the BMI criteria above. It works by selectively activating GLP-1 receptors to suppress appetite and reduce food intake. Learn more in our complete semaglutide guide.
Tirzepatide (Zepbound)
A dual GIP and GLP-1 receptor agonist, also administered as a once-weekly subcutaneous injection. The FDA approved Zepbound for chronic weight management in November 2023. By targeting both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously, tirzepatide has produced greater average weight loss than single-agonist options across clinical trials. See our complete tirzepatide guide for details.
Both medications are available in compounded form through 503A FDA-regulated pharmacies when commercially manufactured versions are unavailable or when individualized dosing is clinically indicated.
4. What the Research Shows for Non-Diabetic Patients
The clinical evidence for GLP-1 in non-diabetic populations is substantial and consistent across multiple large trials.
Semaglutide: STEP 1 Trial
Published in the New England Journal of Medicine in 2021, the STEP 1 trial enrolled 1,961 non-diabetic adults with obesity or overweight plus a weight-related condition. Participants received once-weekly semaglutide 2.4 mg over 68 weeks. The semaglutide group lost an average of 14.9 percent of their starting body weight, compared to 2.4 percent in the placebo group. For a person starting at 200 pounds, that is approximately 30 pounds of weight loss.
Tirzepatide: SURMOUNT-1 Trial
Published in the New England Journal of Medicine in 2022, the SURMOUNT-1 trial enrolled 2,539 non-diabetic adults with obesity or overweight plus a comorbidity. Participants receiving tirzepatide 15 mg achieved an average weight loss of 20.9 percent over 72 weeks, compared to 3.1 percent with placebo. At the highest dose, more than one-third of participants lost 25 percent or more of their starting body weight.
A 2024 systematic review published in PubMed Central confirmed these findings: GLP-1 receptor agonists consistently produce clinically significant weight loss in non-diabetic patients, with results that substantially exceed what is typically achievable through lifestyle modification alone.
5. Why Medication Alone Will Not Keep the Weight Off
This is the piece most providers leave out, and it matters.
A 2022 study published in Diabetes, Obesity and Metabolism followed participants who had completed a semaglutide trial and then discontinued the medication. Within one year of stopping, participants regained approximately two-thirds of their lost weight. Their appetite levels, blood sugar markers, and cardiometabolic risk factors largely returned to baseline. The weight did not stay off simply because it had been lost.
This is not a personal failure. It reflects two gaps that medication alone cannot close.
Gap 1: Nutrition Built for GLP-1 Physiology
When appetite drops significantly on a GLP-1, many patients eat too little overall. The result is muscle loss rather than fat loss, because the body breaks down lean tissue for energy when protein intake is insufficient. Most standard nutrition plans were designed for people who feel hungry. They do not account for the dramatically different nutritional demands of someone on appetite-suppressing therapy.
The GLP-1 Nutrition Protocol™ was built specifically for how GLP-1 changes the body: protein prioritized to protect muscle mass, fiber and hydration managed around the medication’s effects on digestion, a meal structure that works when appetite is low, and eating habits designed to hold when cravings eventually return. It is a 7-module, 26-lesson program included free with every Telezen MD treatment plan.
Gap 2: The Behavioral Root of Weight Regain
Emotional eating, stress-driven food choices, childhood food programming, and the subconscious weight set point are not resolved by appetite suppression. When the medication eventually ends or is reduced, those patterns remain. Lose It for Life™ is a 10-module digital course, also included free, created by Telezen MD co-founder Lina Viner. Through The Rewire Method™, the program works at the subconscious level to address the beliefs and patterns that typically cause weight to return after any medical intervention.
“Medical science takes the weight off. Mind science keeps it off. Lose the weight for life.”
No other GLP-1 telehealth provider combines medical therapy, a purpose-built nutrition system, and a behavioral reprogramming course in a single program. View the full Telezen MD GLP-1 Weight Loss Program.
6. How to Get GLP-1 Safely Without a Diabetes Diagnosis
GLP-1 medications are being sold on social media as “research peptides” available without a prescription. To use them, you would need to reconstitute the compound yourself, estimate your own dose, and inject without medical guidance. There is no way to verify the purity, concentration, or origin of an unregulated product. Contamination and incorrect dosing are real risks.
All GLP-1 medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. That means licensed pharmacists, sterile compounding conditions, and batch testing for potency and purity. Every prescription comes with medical oversight from a licensed provider, and patients have access to a real person at any point in their care.
Getting started through our online GLP-1 treatment program is straightforward:
- Complete an intake with your medical history
- Choose a plan within the intake
- Submit the completed intake
- Your medical team reviews within 24 hours and issues a prescription
- Medication ships to your door
No labs. No clinic visit.
Frequently Asked Questions
Can you use GLP-1 for weight loss if you are not diabetic?
Yes. The FDA approved semaglutide (Wegovy) and tirzepatide (Zepbound) for chronic weight management in non-diabetic adults. Eligibility is based on BMI and the presence of weight-related health conditions, not blood sugar status.
What BMI do you need to qualify for GLP-1 without diabetes?
A BMI of 30 or higher qualifies without any additional conditions. A BMI of 27 or higher qualifies with at least one weight-related condition such as high blood pressure, high cholesterol, insulin resistance, or PCOS. A licensed provider makes the final eligibility determination.
How much weight can non-diabetics lose on GLP-1?
The STEP 1 trial showed an average of 14.9 percent body weight loss with semaglutide over 68 weeks in non-diabetic adults. The SURMOUNT-1 trial showed up to 20.9 percent with tirzepatide over 72 weeks. Individual results vary based on the medication, dose, adherence, and starting metabolic profile.
What happens to the weight when you stop taking GLP-1?
Research shows most patients regain a significant portion of lost weight after stopping. A 2022 study in Diabetes, Obesity and Metabolism found approximately two-thirds of weight was regained within a year of discontinuing semaglutide. This is why Telezen MD pairs every prescription with the GLP-1 Nutrition Protocol™ and Lose It for Life™.
Do you need bloodwork or labs to get a GLP-1 prescription through Telezen MD?
No. Telezen MD does not require lab testing. You complete an online medical intake, and a licensed provider reviews it and issues a prescription within 24 hours if you qualify. Medication ships to your door from there.
What is the difference between a prescription GLP-1 and a research peptide?
Research peptides are sold without prescriptions, often with no quality controls, no medical oversight, and no verified sourcing. Prescription GLP-1 through Telezen MD is compounded by 503A FDA-regulated pharmacies with sterility testing, batch-verified potency, and licensed pharmacist oversight.
GLP-1 medications represent a clinically proven option for weight loss in non-diabetic adults. The eligibility criteria are broader than most people expect, the research is consistent across multiple large trials, and getting started is more accessible than most people realize. The patients who achieve the most lasting results do not just fill a prescription. They pair the medication with a nutrition system built for GLP-1 physiology and a behavioral program that addresses the root causes of weight regain.
Telezen MD combines your GLP-1 prescription with the GLP-1 Nutrition Protocol™ and Lose It for Life™ — two programs built to keep the weight off after the medication does its job. Start your intake today.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384:989–1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022;24(8):1553–1564. https://doi.org/10.1111/dom.14725
- Efficacy of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists for Weight Loss Management in Non-Diabetic Patients. National Library of Medicine. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11335185/
- U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management in Adults. June 2021. FDA.gov
- U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. November 2023. FDA.gov
Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Telezen MD services are available only to patients who qualify following an online medical evaluation with a licensed healthcare provider. Results vary by individual. GLP-1 medications prescribed through Telezen MD are compounded by 503A FDA-regulated pharmacies. Compounded medications are not reviewed or approved by the FDA for safety or efficacy. Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any new medical treatment. If you experience any adverse effects, contact your provider immediately.
